(Q37943841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Pamela N Munster

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

1 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1565-1574

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Next generation topoisomerase I inhibitors: Rationale and biomarker strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Improving melanoma classification by integrating genetic and morphologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Immunotherapy as part of a multidisciplinary approach to melanoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617740

10.1517/13543784.2011.617740

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21985236%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference